Intellia Therapeutics, Inc. (NTLA): Price and Financial Metrics

Intellia Therapeutics, Inc. (NTLA): $30.41

0.52 (-1.68%)

POWR Rating

Component Grades








Add NTLA to Watchlist
Sign Up

Industry: Biotech




#334 of 342

in industry

NTLA Price/Volume Stats

Current price $30.41 52-week high $51.94
Prev. close $30.93 52-week low $22.67
Day low $30.07 Volume 594,260
Day high $31.86 Avg. volume 1,070,121
50-day MA $28.55 Dividend yield N/A
200-day MA $37.05 Market Cap 2.72B

NTLA Stock Price Chart Interactive Chart >


  • Sentiment is the dimension where NTLA ranks best; there it ranks ahead of 27.98% of US stocks.
  • NTLA's strongest trending metric is Growth; it's been moving down over the last 177 days.
  • NTLA ranks lowest in Momentum; there it ranks in the 6th percentile.

NTLA Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for NTLA is 0.05 -- better than merely 11.63% of US stocks.
  • Of note is the ratio of INTELLIA THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; just 7.77% of US stocks have a lower such ratio.
  • NTLA's price/sales ratio is 41.75; that's higher than the P/S ratio of 96.78% of US stocks.
  • If you're looking for stocks that are quantitatively similar to INTELLIA THERAPEUTICS INC, a group of peers worth examining would be DNLI, IGMS, MORF, ARWR, and RNA.
  • Visit NTLA's SEC page to see the company's official filings. To visit the company's web site, go to

NTLA Valuation Summary

  • NTLA's price/sales ratio is 48; this is 2723.53% higher than that of the median Healthcare stock.
  • Over the past 91 months, NTLA's EV/EBIT ratio has gone up 45.3.

Below are key valuation metrics over time for NTLA.

Stock Date P/S P/B P/E EV/EBIT
NTLA 2023-11-03 48.0 2.3 -5.6 -5.5
NTLA 2023-11-02 44.2 2.1 -5.2 -5.1
NTLA 2023-11-01 42.5 2.0 -5.0 -4.9
NTLA 2023-10-31 41.8 2.0 -4.9 -4.8
NTLA 2023-10-30 39.8 1.9 -4.7 -4.5
NTLA 2023-10-27 38.6 1.9 -4.5 -4.4

NTLA Growth Metrics

    Its 2 year revenue growth rate is now at -16.95%.
  • Its 3 year price growth rate is now at 237.58%.
  • Its 4 year cash and equivalents growth rate is now at -68.55%.
NTLA's revenue has moved up $22,899,000 over the prior 52 months.

The table below shows NTLA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 52.121 -333.287 -474.186
2022-09-30 51.402 -298.069 -442.016
2022-06-30 45.34 -284.565 -400.431
2022-03-31 37.86 -252.455 -368.559
2021-12-31 33.053 -225.03 -267.892
2021-09-30 26.794 -210.605 -228.847

NTLA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NTLA has a Quality Grade of D, ranking ahead of 18.09% of graded US stocks.
  • NTLA's asset turnover comes in at 0.066 -- ranking 302nd of 681 Pharmaceutical Products stocks.
  • AGIO, CMRX, and JAZZ are the stocks whose asset turnover ratios are most correlated with NTLA.

The table below shows NTLA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.066 1 -0.397
2021-03-31 0.088 1 -0.420
2020-12-31 0.120 1 -0.510
2020-09-30 0.156 1 -0.586
2020-06-30 0.137 1 -0.536
2020-03-31 0.135 1 -0.414

NTLA Price Target

For more insight on analysts targets of NTLA, see our NTLA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $176.19 Average Broker Recommendation 1.47 (Moderate Buy)

Intellia Therapeutics, Inc. (NTLA) Company Bio

Intellia Therapeutics a gene editing company, develops therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.

NTLA Latest News Stream

Event/Time News Detail
Loading, please wait...

NTLA Latest Social Stream

Loading social stream, please wait...

View Full NTLA Social Stream

Latest NTLA News From Around the Web

Below are the latest news stories about INTELLIA THERAPEUTICS INC that investors may wish to consider to help them evaluate NTLA as an investment opportunity.

Intellia (NTLA) Rises on EC's Orphan Drug Tag for HAE Candidate

The European Commission bestows orphan drug designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, for treating hereditary angioedema. Stock rises.

Yahoo | November 15, 2023

Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

CAMBRIDGE, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative single-dose therapeutics leveraging CRISPR-based technologies, today announced that the European Commission (EC) has granted orphan drug designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to prevent potentially life-thre

Yahoo | November 14, 2023

Need To Know: Analysts Are Much More Bullish On Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenues

Celebrations may be in order for Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) shareholders, with the analysts delivering...

Yahoo | November 14, 2023

Intellia (NTLA) Beats on Q3 Earnings, Provides Pipeline Update

Intellia (NTLA) reports mixed third-quarter 2023 results. Management provides developmental and regulatory updates on its key pipeline candidates.

Yahoo | November 10, 2023

3 Biotech Stocks That Are Betting on the Future of Gene Editing 

These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now.

Chris Markoch on InvestorPlace | November 9, 2023

Read More 'NTLA' Stories Here

NTLA Price Returns

1-mo 21.40%
3-mo -19.32%
6-mo -25.76%
1-year -40.91%
3-year -22.56%
5-year 69.79%
YTD -12.84%
2022 -70.49%
2021 117.35%
2020 270.82%
2019 7.47%
2018 -28.98%

Continue Researching NTLA

Want to see what other sources are saying about Intellia Therapeutics Inc's financials and stock price? Try the links below:

Intellia Therapeutics Inc (NTLA) Stock Price | Nasdaq
Intellia Therapeutics Inc (NTLA) Stock Quote, History and News - Yahoo Finance
Intellia Therapeutics Inc (NTLA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!